Ultimovacs Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • ULTI

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.86
  • (As of Tuesday Closing)

Ultimovacs General Information

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
OSL
Corporate Office
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway
+47 413 00 000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ultimovacs Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.86 $0.70 $0.57 - $16.30 $24.1M 34.4M 1.08M -$0.49

Ultimovacs Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (607) 387,756 338,210 398,244
Revenue 0 0 0 0
EBITDA (16,743) (18,938) (18,010) (19,142)
Net Income (16,688) (17,866) (17,362) (19,100)
Total Assets 28,430 34,319 52,003 74,314
Total Debt 330 365 559 236
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ultimovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product cand
Drug Discovery
Oslo, Norway
25 As of 2024
00000
000000000 00000

000000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000000
Tuebingen, Germany
000 As of 0000
00000
00000000 00000

000000

im ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000 000000000
Oslo, Norway
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ultimovacs Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Formerly VC-backed Tuebingen, Germany 000 00000 00000000 00000
Zelluna Immunotherapy Venture Capital-Backed Oslo, Norway 00 00.000 0000000000 0 00.000
BioNTech Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
APEIRON Biologics Venture Capital-Backed Vienna, Austria 00 000.00 000000 - 000 000.00
Agenus Formerly VC-backed Lexington, MA 000 00000 000000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

Ultimovacs Patents

Ultimovacs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022171684-A Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 0000000000000
AU-2017275782-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 0000000000000
US-20230049012-A1 Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Pending 02-Jun-2016 0000000000000
US-11419927-B2 Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016 0000000000000 00
US-20190247482-A1 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Active 02-Jun-2016 A61K39/001157
To view Ultimovacs’s complete patent history, request access »

Ultimovacs Executive Team (10)

Name Title Board Seat Contact Info
Carlos de Sousa MD Chief Executive Officer
Hans Eid Chief Financial Officer, Finance
Audun Tornes Chief Technology Officer
Gustav Gaudernack Chief Scientific Officer
Ton Berkien Chief Business Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Ultimovacs Board Members (12)

Name Representing Role Since
000 0000000 Ultimovacs Board Member 000 0000
000000 0000000 Self Board Member 000 0000
000000 000000000 Gjelsten Holding Board Member 000 0000
00000 000000000 00 Ultimovacs Chairman & Board Member 000 0000
0000 000000 Ultimovacs Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Ultimovacs Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ultimovacs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Affyn 30-Jan-2022 00000 0000 0000 Entertainment Software
Ultimovacs (Drug Discovery) 11-Jul-2018 Buyout/LBO 00.000 Drug Discovery Ø00000 00
To view Ultimovacs’s complete investments history, request access »

Ultimovacs Subsidiaries (1)

Company Name Industry Location Founded
Ultimovacs (Drug Discovery) Drug Discovery Uppsala, Sweden 0000
To view Ultimovacs’s complete subsidiaries history, request access »

Ultimovacs ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

17.03 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

0.00

Percentile

Biotechnology

Subindustry

0. of 405

Rank

0.00

Percentile

To view Ultimovacs’s complete esg history, request access »

Ultimovacs FAQs

  • When was Ultimovacs founded?

    Ultimovacs was founded in 2011.

  • Who is the CEO of Ultimovacs?

    Carlos de Sousa MD is the CEO of Ultimovacs.

  • Where is Ultimovacs headquartered?

    Ultimovacs is headquartered in Oslo, Norway.

  • What is the size of Ultimovacs?

    Ultimovacs has 25 total employees.

  • What industry is Ultimovacs in?

    Ultimovacs’s primary industry is Drug Discovery.

  • Is Ultimovacs a private or public company?

    Ultimovacs is a Public company.

  • What is Ultimovacs’s stock symbol?

    The ticker symbol for Ultimovacs is ULTI.

  • What is the current stock price of Ultimovacs?

    As of 11-Jun-2024 the stock price of Ultimovacs is $0.86.

  • What is the current market cap of Ultimovacs?

    The current market capitalization of Ultimovacs is $24.1M.

  • Who are Ultimovacs’s competitors?

    Immatics, Zelluna Immunotherapy, BioNTech, APEIRON Biologics, and Agenus are some of the 11 competitors of Ultimovacs.

  • What is Ultimovacs’s annual earnings per share (EPS)?

    Ultimovacs’s EPS for 12 months was -$0.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »